Clinically relevant therapeutic endpoints in type I Gaucher disease
- 176 Downloads
The introduction of enzyme supplementation therapy for Gaucherdisease has had a great impact on the lives of many patients. Organomegaly, cytopenia and bone disease have been shown to improve in response to treatment, resulting in an improvement in quality of life. However, the assessment of organ system involvement is not always done in such a way that the relationship with clinically relevant endpoints is clear. The lack of adequately validated methods of assessment, especially for bone disease, has hindered the establishment of treatment goals and guidelines for treatment optimization.
KeywordsEnzyme Replacement Therapy Gauche Disease Liver Volume Enzyme Therapy Gauche Cell
Unable to display preview. Download preview PDF.
- Beutler E, Grabowski G (1995) Gaucher disease. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease, 7th edn. New York: McGraw-Hill Publishing Company.Google Scholar
- Ek M, Guijt M, Oosterveld P, Hollak CEM (1999) Quality of life in patients with Gaucher disease in the Netherlands. Abstract, 3rd Meeting of the European Working Group on Gaucher Disease, Lemnos: 18.Google Scholar
- Maas M, Akkerman EM, Hollak CEM, et al (1999) Radiological, biochemical and clinical parameters of skeletal disease in relation to fat fraction determination by QCSI in type 1 Gaucher disease. Abstract, 3rd Meeting of the European Working Group on Gaucher Disease, Lemnos: 40.Google Scholar
- Van Weely S, Hollak CE, Maas M, Boot RG, Aerts JM (1999) Determination of plasma chitotriosidase in Gaucher disease: practical implications. Abstract, 3rd Meeting of the European Working Group on Gaucher Disease, Lemnos: 71.Google Scholar